KURA · Kura Oncology, Inc. · Stock research

Current Thesis

The re-rating already fired. Ziftomenib (KOMZIFTI) won FDA approval on 2025-11-13 for relapsed/refractory NPM1-mutant AML — the first once-daily oral menin inhibitor — and the stock ran from a $5.45 pre-approval low (2025-08-11) to a $12.49 post-approval high (2025-11-14). Eight-plus months on, the tight consolidation near that high has given way: KURA printed $10.39 on 2026-07-25, drifting into the lower third of the $10–12.5 range it held all of H1 2026. The trade the Street underwrites — frontline AML expansion behind the $24–28 price targets — is gated to a Phase 3 (KOMET-017) that does not read out until 2028. That is a de-risked, target-cheap biotech in a two-year catalyst gap with a slowly eroding tape, not an accelerating narrative a momentum book gets paid to chase. The near-term reads are a 2026-07-27 darlifarnib data call and the second full KOMZIFTI launch quarter, due early August.

Bullish and bearish views on Kura Oncology, Inc.

The model's bull view on Kura Oncology, Inc. (KURA), in brief: KOMZIFTI captured ~40% of new patient starts in R/R NPM1-mutant AML with payer access secured for >93% of covered lives (EHA 2026 / Q1 update, 2026-06-14) — fast share capture in its approved niche. The bear view: The catalyst that mattered is in the rearview. Both cases follow in full.

Bull Case

• KOMZIFTI captured ~40% of new patient starts in R/R NPM1-mutant AML with payer access secured for >93% of covered lives (EHA 2026 / Q1 update, 2026-06-14) — fast share capture in its approved niche.
• Q1 2026 net product revenue $5.8M, the first full commercial quarter, up from a $2.1M launch stub (first sale 2025-11-21 through 2025-12-31) — the sequential ramp is real, not clinical-stage promise.
• Frontline data is strong: KOMET-007 long-term results (2026-06-12) showed 96% CR in NPM1-m and 90% in KMT2A-r, 12-month overall survival 94% / 71%, high MRD-negativity, and a manageable safety profile — one of the larger menin-plus-chemo frontline datasets and the basis for KOMET-017.
• Safety differentiation versus Syndax's revumenib (Revuforj): ziftomenib carries no QTc-prolongation/Torsades boxed warning, which matters as the class pushes into frontline chemo combinations.
• Funded to the binary: ~$580.8M cash and investments at 2026-03-31 plus ~$180M anticipated Kyowa Kirin payments fund the ziftomenib program through the 2028 KOMET-017 top-line; the Kyowa deal (Nov 2024) runs up to $1.161B total with 50/50 US profit share, and a $30M KOMET-017 first-dosing milestone is already paid.
• Second shot on goal: darlifarnib (farnesyl transferase inhibitor) plus cabozantinib in renal cell carcinoma — updated long-term FIT-001 Phase 1a/1b follow-up presented at KCRS 2026 (2026-07-24), with a virtual investor call 2026-07-27.
• Sell-side well above spot: Citizens reiterated Market Outperform, $24 target (2026-06-15); consensus range roughly $16–76 against a $10.39 tape.

Bear Case

• The catalyst that mattered is in the rearview. Approval fired 2025-11-13, and the stock now trades ~17% below its post-approval high and has ground lower through July ($11.44 on 2026-07-10 → $10.39 on 2026-07-25).
• Two-year catalyst desert: the transformative KOMET-017 Phase 3 top-line is not expected until 2028, leaving no binary to force a re-rate and room to bleed.
• Crowded class: Syndax's Revuforj reached market first (covers both KMT2A-r and R/R NPM1); J&J's bleximenib, Sumitomo's enzomenib and Servier's S243249 are advancing. Frontline share is contested, and Kura lost the initial R/R race.
• The approved indication is a narrow R/R NPM1 monotherapy niche; the $24–28 targets require frontline standard-of-care adoption that has not been demonstrated commercially.
• Burn is real: cash fell ~$86M in Q1 ($667.2M at 2025-12-31 → $580.8M at 2026-03-31); runway leans on Kyowa milestones landing on schedule.
• Darlifarnib is early Phase 1 — optionality only; a secondary-asset data call rarely re-rates a whole company on its own.

Setup & Price Structure

• $10.39 (2026-07-25). 52-week range $5.45 (2025-08-11) to $12.49 (2025-11-14, post-approval).
• The H1 2026 range was roughly $10–12.5; price now sits in the lower third and has stepped down through a series of lower highs since the November spike — the post-approval base is softening rather than coiling for a breakout.
• ~$9.50 is the line that matters: a weekly close beneath it breaks the consolidation base and loses the rising 200-day.
• No parabola, no volume expansion, RSI mid-range — dormant, drifting tape and the opposite of a momentum entry. A reclaim of the $12.49 high on expanding volume is the only tell that a fresh leg is starting.

Catalyst Calendar (next 30 days)

• No FDA/PDUFA date or Phase 3 readout in the window; the next transformational binary (KOMET-017) is ~2028.

Elapsed catalysts

• 2026-07-27 — virtual investor call on darlifarnib FIT-001 Phase 1a/1b long-term data (post-KCRS 2026, data shown 2026-07-24). Secondary-asset read with modest move potential. (passed 13d ago)
• ~2026-08-06 (est.) — Q2 2026 financial results, the second full KOMZIFTI launch quarter (Q2 2025 landed 2025-08-07; Q1 2026 on 2026-05-12). The key near-term binary: sequential revenue over $5.8M and durability of the >40% share and payer access. Avoid fresh entries into the print. (passed 3d ago)

What Would Change Our Mind

• Upside re-rate: a weekly close above $12.49 on expanding volume, ideally alongside a Q2 print showing clear sequential acceleration over $5.8M and durable >40% share — that flips the read from dormant to a launch-inflection setup worth chasing.
• Downside confirmation: a weekly close below $9.50 breaking the base and losing the rising 200-day; or a Q2 KOMZIFTI print stalling near Q1's $5.8M; or the menin-inhibitor class flipping to saturated as revumenib and bleximenib take frontline share.
• Frontline optionality: positive KOMET-017 enrollment or interim signals, or an accelerated regulatory path, could compress the 2028 catalyst gap and warrant fresh interest ahead of the print.

Correlation Notes

• Menin-inhibitor / AML complex: trades with Syndax (SNDX, revumenib) as the direct comp; class sentiment swings on frontline data from J&J (bleximenib), Sumitomo (enzomenib) and Servier (S243249).
• Partner read-through: Kyowa Kirin milestone flow and commentary drive the US profit-share narrative and the 2028 runway math.
• Small-cap biotech beta: sensitive to XBI/IBB risk appetite and rate moves; a two-year catalyst gap makes it a low-catalyst, funding-cost-sensitive name that tends to drift with the group rather than lead it.